Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

Nature Clinical Practice Oncology volume 2, pages 126–127 (2005)Cite this article

boxed-textReed SD et al. (2004) Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 101: 2574–2583

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon-alfa 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330: 820–825

  2. Kantarjian H (2004) High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103: 2873–2878

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Hematology of Imperial College at Hammersmith Hospital, London, UK

    John Goldman

  2. National Institutes of Health, Betthesda, MD, USA

    John Goldman

Authors
  1. John Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

IRIS

International Randomized Interferon versus STI571 Study

EURO-QOL-5D

A measure of health-related quality of life

QALY

Quality-adjusted life-years

BCR–ABL

Translation products of a fusion mRNA derived from the breakpoint cluster region (bcr) gene and a cellular abl (c-abl) gene translocated to chromosome 22. The p210(bcr-abl) fusion protein is found in patients with chronic myelogenous leukaemia.

PHILADELPHIA CHROMOSOME

Philadelphia chromosome or Philadelphia translocation is a specific genetic, chromosomal abnormality that is associated with chronic myelogenous leukemia; 95% of patients with CML show this abnormality; the remaining 2–3% harbor a very similar abnormality.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldman, J. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?. Nat Rev Clin Oncol 2, 126–127 (2005). https://doi.org/10.1038/ncponc0110

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0110

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing